Table 3 of
Daruich, Mol Vis 2019; 25:610-624. Table 3 of
Daruich, Mol Vis 2019; 25:610-624.
Table 3. Urso- and Tauroursodeoxycholic acids in different models of retinal disease.
| Biliary acid | Study design | Model (Disease) | Dose/ Concentration | Route | References |
|---|---|---|---|---|---|
| TUDCA | In vivo | rd10 mouse (PR) and LIRD mouse | 500 mg/kg x2 or x4 | Subcutaneous injection | [2] |
| TUDCA | In vivo | rd10 mouse | 500 mg/ kg every 3 days (x8) | Subcutaneous injection | [37] |
| TUDCA | In vivo | rd1 mouse | 500 mg/ kg every 3 days (x5) | Subcutaneous injection | [86] |
| UDCA TUDCA | In vivo | CNV laser-treated rat | TUDCA 500 mg/kg/day. UDCA 100 mg/kg/day Before laser and for 14 days | Intraperitoneal injection | [60] |
| TUDCA | In vivo | P23H rat (PR) | 500 mg/kg once a week (x14) | Intraperitoneal injection | [39] |
| TUDCA | In vivo | Retinal detachment induced Brown Norway rats | 500 mg/kg daily X3 or X5 | Intraperitoneal injection | [43] |
| TUDCA | In vivo | rd10 mouse and LIRD mouse | 500 mg/kg x1 or every 3 day (x14) | Intraperitoneal injection | [36] |
| TUDCA | In vivo | BbsM390R/M390R mice rd10 mouse rd1 and rd16 mice | 500 mg/kg twice a week, (x22) every 3 days (x11) daily (x24) | Subcutaneous injection | [38] |
| TUDCA | In vivo | Lrat–/– mouse (LCA) | 500 mg/kg every 3 days (x6) | Subcutaneous injection | [41] |
| TUDCA | In vitro | Retinal cell exposed to high glucose | 100 µM/day from D2-D7 | - | [55] |
| TUDCA | In vitro | STZ-induced (diabetic) rat retinas | 100 µM/day 7 days | - | [56] |
| TUDCA | In vivo | P23H rat | 500 mg/kg weekly (x14) | Intraperitoneal injection | [44] |
| TUDCA | In vivo | Lrat–/– mouse (LCA) | 500 mg/ kg every 3 days (x8) | Subcutaneous injection | [42] |
| TUDCA | In vivo | NMDA-induced damage in rat | 500 mg/kg/day (x 6) | Intraperitoneal injection | [47] |
| TUDCA | In vitro | Cat retinal ganglion cells | 0.5 μM, 25 ml, 5 min | - | [50] |
| TUDCA | In vitro | SD rats retinal explants cultured in advanced glycation end-products | 100 µM, 7 days | - | [87] |
| TUDCA | In vitro | ARPE-19, primary human RPE cells | 30–300 µM 1 h | - | [45] |
| TUDCA | In vitro In vivo | High glucose-induced HRMECs STZ-induced (diabetic) rat | 5.0μM, 25.0μM and 125.0μM 250mg/kg/d and 500mg/kg/d | [88] | |
| TUDCA | In vitro | Leber hereditary optic neuropathy fibroblasts | 100 µM, 24 h | [51] | |
| TUDCA | In vivo | rd1 mouse | 500 mg/kg every 3 days (x15) | Intraperitoneal injection | [89] |
| UDCA | In vivo | STZ-induced (diabetic) mice | 100 mg/kg/d 6 weeks | Intraperitoneal injection | [57] |
| TUDCA | In vivo | P23H rat | 5.05±0.11 μg /mg microsphere | Intravitreal injection | [90] |
| UDCA | In vivo | STZ-induced (diabetic) mice | 15,30 mg/kg 1 months | Oral | [58] |
| TUDCA | In vivo | Optic nerve crush rat model | 100 mM TUDCA 14 days | Topically, 1 drop every 12 h | [49] |